151 related articles for article (PubMed ID: 12804851)
1. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.
Da Silva DM; Schiller JT; Kast WM
Vaccine; 2003 Jul; 21(23):3219-27. PubMed ID: 12804851
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
3. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
4. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
5. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
[TBL] [Abstract][Full Text] [Related]
6. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
[TBL] [Abstract][Full Text] [Related]
7. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Greenstone HL; Nieland JD; de Visser KE; De Bruijn ML; Kirnbauer R; Roden RB; Lowy DR; Kast WM; Schiller JT
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1800-5. PubMed ID: 9465097
[TBL] [Abstract][Full Text] [Related]
8. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
9. Immunization against human papillomavirus infection and associated neoplasia.
Osen W; Jochmus I; Müller M; Gissmann L
J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
[TBL] [Abstract][Full Text] [Related]
10. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection.
Schäfer K; Müller M; Faath S; Henn A; Osen W; Zentgraf H; Benner A; Gissmann L; Jochmus I
Int J Cancer; 1999 Jun; 81(6):881-8. PubMed ID: 10362134
[TBL] [Abstract][Full Text] [Related]
11. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
12. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
13. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
15. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
17. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
18. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
19. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
20. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
